Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN

The purpose of this study is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of OMS906 in patients with C3 Glomerulopathy (C3G) and Idiopathic Immune Complex-Mediated Glomerulonephritis (ICGN)

Participants needed: 20
Trial details
Phase: Phase 2Age: 18-99Biological sex: AllType: InterventionalSponsor: Omeros CorporationUpdated: Jul 15, 2025Locations: 6
Eligibility criteria

Male or female adults 18 years and older. [+12]

History of major organ transplant or hematopoietic stem cell/marrow transplant. [+18]

Read more
Status: Recruiting

Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA

The purpose of this study is to evaluate the safety and efficacy of narsoplimab in pediatric patients with thrombotic microangiopathies (TMA) following hematopoietic stem cell transplant (HSCT).

Participants needed: 18
Trial details
Phase: Phase 2Age: 28-17Biological sex: AllType: InterventionalSponsor: Omeros CorporationUpdated: Mar 25, 2025Locations: 16
Eligibility criteria

Age at least 28 days and less than 18 years prior to informed consent (Visit 0). [+16]

All treatments for HSCT-TMA are allowed except eculizumab, ravulizumab, and defi... [+12]

Read more
Status: Recruiting

Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria

The purpose of this study is to assess the long-term safety and tolerability of repeat-dose OMS906 5 mg/kg IV administration at 8-week intervals in patients with PNH.

Participants needed: 25
Trial details
Phase: Phase 2Age: 18-99Biological sex: AllType: InterventionalSponsor: Omeros CorporationUpdated: Mar 7, 2024Locations: 5
Eligibility criteria

Have completed the last dosing visit of the prior OMS906 PNH study. [+5]

Platelet count <30,000/µL or absolute neutrophil count <500 cells/µL at the star... [+6]

Read more